Biomarkers /
SLX4
Overview
SLX4 structure-specific endonuclease subunit (SLX4) is a gene that encodes a protein that is part of a complex required for specific types of DNA repair and for cellular responses to replication fork failure. Missense mutations, synonymous mutations, nonsense mutations, and frameshift deletions are observed in cancers such as colon cancer, skin cancer, and stomach cancer.
SLX4 is altered in 3.16% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in SLX4 are SLX4 Mutation (2.79%), SLX4 Loss (0.13%), SLX4 Amplification (0.10%), SLX4 R1021C (0.02%), and SLX4 E179D (0.08%) [3].
Clinical Trials
Significance of SLX4 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.